Arcutis Biotherapeutics
ARQT
ARQT
141 hedge funds and large institutions have $974M invested in Arcutis Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 70 increasing their positions, 27 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
141
Holders Change
+2
Holders Change %
+1.44%
% of All Funds
2.27%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
21
Increased
70
Reduced
27
Closed
19
Calls
$11.2M
Puts
$135K
Net Calls
+$11.1M
Net Calls Change
+$5.6M
Top Buyers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
$40.6M |
| 2 |
Barclays
London,
United Kingdom
|
$17.5M |
| 3 |
State Street
Boston,
Massachusetts
|
$54.5M |
| 4 |
Holocene Advisors
New York
|
$16.9M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
$26M |
